Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age | NEJM
Coronavirus information
Protocol for a multicentre randomised controlled trial examining the effects of temporarily pausing Bruton tyrosine kinase inhibitor therapy to coincide with SARS-CoV-2 vaccination and its impact on immune responses in patients with
GCT to Perform Booster Visits in Russia
Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in adolescents and adults: phase III randomized study | Pediatric Research
COVID-19 Booster Vaccine Study | Suburban Hospital | Johns Hopkins Medicine
Getting a Flu Vaccine and a COVID-19 Vaccine at the Same Time | CDC
Frontiers | Review of Clinical Trials of COVID-19 Vaccination Booster in SARS-CoV-2 Variants Era: To Take It or Not To Take It
COVID vaccinations: questions and answers about the rollout in North Yorkshire - NHS North Yorkshire CCG
Adopting a New Agile Approach to CRO Clinical Trial Management - Clinical Trial Services, UK | PHARMExcel
UK volunteers to receive Moderna Omicron COVID-19 booster vaccine in clinical study | NIHR
Monitoring Visits in Clinical Trials
Safety and immunogenicity of seven COVID-19 vaccines as a third dose ( booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV- BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial -
Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial | Nature Medicine
Department of Health and Social Care on Twitter: "Everyone aged 16 and over is eligible for the #COVID19 booster from three months after their second dose. Book an appointment online or find
Coronavirus (COVID-19) Vaccines | CardioSmart – American College of Cardiology
Looking beyond COVID-19 vaccine phase 3 trials | Nature Medicine
Homologous and Heterologous Covid-19 Booster Vaccinations | NEJM
Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial - The Lancet
PRACT: a pragmatic randomized adaptive clinical trial protocol to investigate a culturally adapted brief negotiational intervention for alcohol use in the emergency department in Tanzania | Trials | Full Text
Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trial -
Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial | Signal Transduction and Targeted Therapy
Immunobridging trials: Bringing medicines to patients faster
